Literature DB >> 32524748

Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.

Anthony Franklin1,2,3, William J Yaxley3,4, Sheliyan Raveenthiran4, Geoff Coughlin1, Troy Gianduzzo1,3, Boon Kua1, Lousie McEwan5, David Wong5, Brett Delahunt6,7, Lars Egevad8, Hema Samaratunga6, Nicholas Brown3,5, Rob Parkinson5, Matthew J Roberts3,4, John W Yaxley1,3,4.   

Abstract

OBJECTIVE: To evaluate the ability of preoperative multiparametric magnetic resonance imaging (mpMRI) and a gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (68 Ga-PSMA PET/CT) scan to predict pathological outcomes and also identify a group of men with a <5% risk of histological pelvic lymph node metastasis (LNM) at pelvic lymph node dissection (PLND) performed during a robot-assisted laparoscopic radical prostatectomy (RALP) for prostate cancer. We then aimed to compare these results to known risk calculators for LNM, including the Cancer of the Prostate Risk Assessment (CAPRA) score, Memorial Sloan Kettering Cancer Centre (MSKCC) and Briganti nomograms. PATIENTS AND METHODS: Between July 2014 and September 2019 only men who had both a preoperative mpMRI and staging 68 Ga-PSMA PET/CT at our institution followed by a RALP with PLND referred to a single specialist uropathology laboratory were considered for inclusion. The data were collected retrospectively prior to February 2019 and in a prospective manner thereafter. A model was built to allocate probabilities of the men with a negative 68 Ga-PSMA PET/CT scan having a <5% risk of histologically LNM at RALP based on the preoperative radiological staging.
RESULTS: A total of 233 consecutive men met the inclusion criteria of which 58 men (24.9%) had a LNM identified on PLND histology. The median (range) International Society of Urological Pathology (ISUP) Grade was 5 (1-5) and the median (range) prostate-specific antigen level was 7.4 (1.5-72) ng/mL. The median (range) number of resected lymph nodes was 16 (1-53) and the median (range) number of positive nodes identified on histology was 2 (1-22). Seminal vesicle invasion on mpMRI was more common in node-positive men than in the absence of LNM (31% vs 12%). The maximum standardised uptake value of the primary tumour on 68 Ga-PSMA PET/CT was higher in men with LNM (median 9.2 vs 7.2, P = 0.02). Suspected LNM were identified in 42/233 (18.0%) men with 68 Ga-PSMA PET/CT compared with 22/233 (9.4%) men with mpMRI (P = 0.023). The positive and negative predictive value for 68 Ga-PSMA PET/CT was 66.7% and 84.3% respectively, compared to 59.1% and 78.7% for mpMRI. A predictive model showed only two men (4.2%) with a negative preoperative 68 Ga-PSMA PET/CT would be positive for a histological LNM if they are ISUP Grade < 5 and Prostate Imaging-Reporting and Data System (PI-RADS) <5; or ISUP Grade 5 with PI-RADS < 4. An inspection of three additional variables: CAPRA score, MSKCC and Briganti nomograms did not improve the predictive probability for this group. However, of the 61 men with ISUP Grade 4-5 malignancy and also a PI-RADS 5 mpMRI, 20 (32.8%) men had a microscopic LNM despite a negative preoperative 68 Ga-PSMA PET/CT.
CONCLUSION: Preoperative 68 Ga-PSMA/PET CT was more sensitive in identifying histological pelvic LNM than 3-T mpMRI. Men with a negative 68 Ga-PSMA PET/CT have a lower risk of LNM than predicted with CAPRA scores or MSKCC and Briganti nomograms. We identified that the combination of a negative preoperative 68 Ga-PSMA PET/CT, ISUP biopsy Grade <5 and PI-RADS <5 prostate mpMRI, or an ISUP Grade 5 with PI-RADS <4 on mpMRI was associated with a <5% risk of a LNM. The addition of CAPRA scores, MSKCC and Briganti nomograms did not improve the predictive probability within this model. Conversely, men with ISUP Grade 4-5 malignancy associated with a PI-RADS 5 prostate mpMRI had a >30% risk of microscopic LNM despite a negative preoperative 68 Ga-PSMA PET/CT and this high-risk group would appear suitable for an extended PLND at the time of a radical prostatectomy.
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #PCSM; #ProstateCancer; MRI prostate; PET PSMA scan; metastasis; pelvic lymph node; primary staging; prostate cancer

Year:  2020        PMID: 32524748     DOI: 10.1111/bju.15134

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

1.  Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.

Authors:  Álan Roger Gomes Barbosa; Breno Santos Amaral; Danilo Budib Lourenço; Bianca Bianco; Felipe Arakaki Gushiken; Marcelo Apezzato; Júlia Francisco Silva; Marcelo Livorsi da Cunha; Reneé Zon Filippi; Ronaldo Hueb Baroni; Gustavo Caserta Lemos; Arie Carneiro
Journal:  Einstein (Sao Paulo)       Date:  2022-05-16

2.  Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy.

Authors:  Matthew J Roberts; Andrew Morton; Nathan Papa; Anthony Franklin; Sheliyan Raveenthiran; William J Yaxley; Geoffrey Coughlin; Troy Gianduzzo; Boon Kua; Louise McEwan; David Wong; Brett Delahunt; Lars Egevad; Hemamali Samaratunga; Nicholas Brown; Robert Parkinson; Louise Emmett; John W Yaxley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-17       Impact factor: 10.057

3.  Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.

Authors:  Christian Pirich; Mohsen Beheshti; Florian Szigeti; Gregor Schweighofer-Zwink; Matthias Meissnitzer; Cornelia Hauser-Kronberger; Wolfgang Hitzl; Thomas Kunit; Rosemarie Forstner
Journal:  Mol Imaging Biol       Date:  2021-09-14       Impact factor: 3.488

4.  Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and Multiparametric MRI for Pelvic Lymph Node Staging Prior to Radical Prostatectomy in Patients With Intermediate to High-Risk Prostate Cancer: A Meta-Analysis.

Authors:  Xueju Wang; Qiang Wen; Haishan Zhang; Bin Ji
Journal:  Front Oncol       Date:  2021-10-20       Impact factor: 6.244

Review 5.  Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Sui Wai Ling; Anouk C de Jong; Ivo G Schoots; Kazem Nasserinejad; Martijn B Busstra; Astrid A M van der Veldt; Tessa Brabander
Journal:  Eur Urol Open Sci       Date:  2021-09-28

6.  Could 68Ga-PSMA PET/CT Evaluation Reduce the Number of Scheduled Prostate Biopsies in Men Enrolled in Active Surveillance Protocols?

Authors:  Pietro Pepe; Marco Roscigno; Ludovica Pepe; Paolo Panella; Marinella Tamburo; Giulia Marletta; Francesco Savoca; Giuseppe Candiano; Sebastiano Cosentino; Massimo Ippolito; Andreas Tsirgiotis; Michele Pennisi
Journal:  J Clin Med       Date:  2022-06-16       Impact factor: 4.964

Review 7.  A review of artificial intelligence in prostate cancer detection on imaging.

Authors:  Indrani Bhattacharya; Yash S Khandwala; Sulaiman Vesal; Wei Shao; Qianye Yang; Simon J C Soerensen; Richard E Fan; Pejman Ghanouni; Christian A Kunder; James D Brooks; Yipeng Hu; Mirabela Rusu; Geoffrey A Sonn
Journal:  Ther Adv Urol       Date:  2022-10-10

8.  Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Authors:  William John Yaxley; Rhiannon McBean; David Wong; David Grimes; Paul Vasey; Mark Frydenberg; John William Yaxley
Journal:  Investig Clin Urol       Date:  2021-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.